Oncotarget

Meta-Analysis:

The prognostic role of Sirt1 expression in solid malignancies: a meta-analysis

Changwen Wang, Wen Yang, Fang Dong, Yawen Guo, Jie Tan, Shengnan Ruan and Tao Huang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:66343-66351. https://doi.org/10.18632/oncotarget.18494

Metrics: PDF 1201 views  |   HTML 3510 views  |   ?  


Abstract

Changwen Wang1,*, Wen Yang1,*, Fang Dong1, Yawen Guo1, Jie Tan1, Shengnan Ruan1 and Tao Huang1

1Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

*These authors contributed equally to this work

Correspondence to:

Tao Huang, email: [email protected]

Shengnan Ruan, email: [email protected]

Keywords: Sirt1, solid malignancy, prognosis, meta-analysis

Received: January 21, 2017     Accepted: May 29, 2017     Published: June 15, 2017

ABSTRACT

Although many studies have discussed the association of abnormally expressed silent information regulator 1 (Sirt1) with the prognosis of patients with a variety of solid carcinomas, they failed to agree on whether excessive Sirt1 indicates a good or poor overall survival for the patients. We conducted the current meta-analysis to illustrate the prognostic value of Sirt1 in solid malignancies. Articles published before December 2016 were searched using Pubmed and Web of Science. The studies were selected for the meta-analysis based on certain criteria. A total of 7,369 cases from 37 studies were included, in which 48.6% of the patients overexpressed Sirt1. The overall survival (OS) and clinical features, such as age and TNM stage, were analyzed using RevMan 5.3 software. Sirt1 overexpression was significantly correlated with the OS (HR: 1.52, 95% CI: [1.23, 1.88], P = 0.0001), especially in liver cancer (HR: 1.78, 95% CI: [1.46, 2.18], P < 0.00001) and lung cancer (HR: 1.80, 95% CI: [1.06, 3.05], P = 0.03), which suggested that the overexpression of Sirt1 indicates poor prognosis of patients with solid cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18494